Prophylactic Ivermectin in COVID-19 Contacts

Official Title

Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19

Brief Summary

asymptomatic family close contact of confirmed COVID -19 patient will receive prophylactic ivermectin and will be followed up for 14 days for any symptoms & diagnosis of COVID -19

Status

Completed

Conditions

COVID

Interventions

Drug: Ivermectin Tablets

two doses 72 hours apart

Eligibility Criteria

Inclusion Criteria:

family contact of confirmed COVID-19 case

Exclusion Criteria:

- refuse to participate and receive the drug pregnancy or lactation known
hypersensitivity to ivermectin

Eligibility Gender

All

Eligibility Age

Minimum: 16 Years ~ Maximum: 70 Years

Countries

Egypt

Locations

Zagazig University
Zagazig, Sharkia, Egypt

NCT Number

NCT04422561

MeSH Terms

Ivermectin

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

Zagazig University

Prophylactic Ivermectin in COVID-19 Contacts

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA